The efficacy of previous clinical trials has not been too encouraging, but the efficacy of the combination of new drugs (e.g., CDK2 inhibitors, daratumumab, midostaurin, etc.)and ATRA in the treatment of non-APL AML still deserves to be further investigated. Here, CDK2 is linked to acute myeloid leukemia.